Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 15/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521480 | 0.77 | ALDH1A1 (0.43) | NMT1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4170922 | 0.75 | NMT1 (0.40) | NMT1 | |
| SCHEMBL4163141 | 0.72 | CHEK1 (0.34) | NMT1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1069804 | 0.71 | GPR119 (0.33) | — | |
| Tert-Butyl Formate SCHEMBL28766881 | 0.70 | TLR9 (0.38) | NMT1 | |
| SCHEMBL27939043 | 0.69 | TLR9 (0.37) | NMT1KCNH2 | |
| Formic Acid Phenyl Ester SCHEMBL27657419 | 0.69 | MAOB (0.39) | NMT1 | |
| SCHEMBL389991 | 0.68 | GPR119 (0.47) | — | |
| SCHEMBL13186626 | 0.66 | NMT1 (0.40) | NMT1 | |
| SCHEMBL14640649 | 0.65 | USP7 (0.43) | NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |